Clinical Performance Evaluation of the Bio-Self™ COVID-19 Antigen Home Test

NCT ID: NCT05334758

Last Updated: 2024-03-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

282 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-12

Study Completion Date

2022-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the performance of the Bio-Self COVID-19 Antigen Home Test. The study will evaluate the accuracy (sensitivity and specificity) in a simulated home use environment when compared to a high-sensitivity Emergency Use Authorization (EUA) SARS-CoV-2 RT-PCR assay.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Bio-Self COVID-19 Antigen Home Test is immunochromatographic and uses double-antibody sandwich method to detect SARS-CoV-2 antigen from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection. The test is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older or adult collected anterior nares swab samples from individuals ages 2 to 13.

The primary objective of this study is to determine the accuracy of the Bio-Self COVID-19 Antigen Home Test when compared to a high-sensitivity Emergency Use Authorization (EUA) SARS-CoV-2 RT-PCR assay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

This is an open label, prospective study to evaluate the sensitivity and specificity of the Bio-Self COVID-19 Antigen Home Test when a lay person conducts the test on themselves or another study participant. Potential subjects will be those presenting for COVID-19 testing. The study will evaluate the performance of the Bio-Self COVID-19 Antigen Home Test by comparing it to a high sensitivity EUA SARS-CoV-2 RT-PCR assay to calculate both the positive percent agreement \[(PPA) sensitivity\] and negative percent agreement \[(NPA) specificity\].
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

At least 30 children between 2 - 13 years of age

Subjects less than 14 years of age, where the Parent or legal guardian collects a sample from their child (e.g., ages 2-13) and performs the Bio-Self COVID-19 antigen home test. The standard of care test and the RT-PCR test samples will be collected by the study team.

Group Type EXPERIMENTAL

Bio-Self COVID-19 Antigen Home Test

Intervention Type DEVICE

At home COVID-19 antigen test kit

Standard of Care COVID-19 Test

Intervention Type DEVICE

Standard of care

RT-PCR Test

Intervention Type DIAGNOSTIC_TEST

High Sensitivity RT-PCR COVID-19 Test

Subjects 14 - 90 years of age

The subject will self collect and test using the Bio-Self COVID-19 antigen home test. The standard of care test and the RT-PCR test samples will be collected by the study team.

Group Type EXPERIMENTAL

Bio-Self COVID-19 Antigen Home Test

Intervention Type DEVICE

At home COVID-19 antigen test kit

Standard of Care COVID-19 Test

Intervention Type DEVICE

Standard of care

RT-PCR Test

Intervention Type DIAGNOSTIC_TEST

High Sensitivity RT-PCR COVID-19 Test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bio-Self COVID-19 Antigen Home Test

At home COVID-19 antigen test kit

Intervention Type DEVICE

Standard of Care COVID-19 Test

Standard of care

Intervention Type DEVICE

RT-PCR Test

High Sensitivity RT-PCR COVID-19 Test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. An Institutional Review Board (IRB) approved informed consent and assent, if applicable, is signed and dated prior to any study-related activities.
2. Male and female Subjects 2 years of age and older.
3. Subject is willing to provide a self-collected nasal swab sample. (If under the age of 14, the sample will be collected by an adult.)
4. Subject is willing to have a nasal swab collected by a healthcare professional.
5. Subject agrees to complete all aspects of the study.

Exclusion Criteria

1. Subject has a visual impairment that cannot be restored with glasses or contact lenses.
2. Subject has prior medical or laboratory training.
3. Subject had a positive COVID-19 test in past three (3) months.
4. Subject uses home diagnostics, e.g., HIV Tests, glucose meters, etc.
Minimum Eligible Age

2 Years

Maximum Eligible Age

94 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CSSi Life Sciences

INDUSTRY

Sponsor Role collaborator

BioTeke USA, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven Geller, MD

Role: PRINCIPAL_INVESTIGATOR

Centennial Medical Group

Enrique Villa, MD

Role: PRINCIPAL_INVESTIGATOR

L&A Morales Healthcare

Narendra Kini, MD

Role: PRINCIPAL_INVESTIGATOR

CDR Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

L&A Morales Healthcare, Inc.

Miami, Florida, United States

Site Status

CDR Health

Tallahassee, Florida, United States

Site Status

Centennial Medical

Elkridge, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BTK-01-1002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.